NanoEcho advanced its clinical program for rectal cancer diagnostics, secured new financing, and completed product development, while reporting a net loss and no revenue as it remains in the clinical phase. The company targets regulatory approval in 2027.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.